Georgia
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1.48 (1.46 - 1.50) | 2019 | Modelled | IHME |
| 1.49 (1.48 - 1.51) | 2018 | Modelled | IHME |
| 1.51 (1.49 - 1.53) | 2017 | Modelled | IHME |
| 1.54 (1.52 - 1.56) | 2016 | Modelled | IHME |
| 1.57 (1.55 - 1.59) | 2015 | Modelled | IHME |
| 1.61 (1.59 - 1.63) | 2014 | Modelled | IHME |
| 1.65 (1.63 - 1.67) | 2013 | Modelled | IHME |
| 1.69 (1.67 - 1.71) | 2012 | Modelled | IHME |
| 1.73 (1.71 - 1.75) | 2011 | Modelled | IHME |
| 1.76 (1.74 - 1.78) | 2010 | Modelled | IHME |
| 1.79 (1.76 - 1.81) | 2009 | Modelled | IHME |
| 1.81 (1.79 - 1.83) | 2008 | Modelled | IHME |
| 1.83 (1.81 - 1.85) | 2007 | Modelled | IHME |
| 1.85 (1.82 - 1.87) | 2006 | Modelled | IHME |
| 1.87 (1.84 - 1.90) | 2005 | Modelled | IHME |
| 1.9 (1.87 - 1.93) | 2004 | Modelled | IHME |
| 1.93 (1.90 - 1.96) | 2003 | Modelled | IHME |
| 1.97 (1.93 - 2) | 2002 | Modelled | IHME |
| 1.99 (1.95 - 2.03) | 2001 | Modelled | IHME |
| 2 (1.96 - 2.04) | 2000 | Modelled | IHME |
| 2 (1.96 - 2.03) | 1999 | Modelled | IHME |
| 1.99 (1.95 - 2.02) | 1998 | Modelled | IHME |
| 1.97 (1.94 - 2.01) | 1997 | Modelled | IHME |
| 1.96 (1.93 - 2) | 1996 | Modelled | IHME |
| 1.95 (1.92 - 1.99) | 1995 | Modelled | IHME |
| 1.95 (1.91 - 1.98) | 1994 | Modelled | IHME |
| 1.94 (1.91 - 1.98) | 1993 | Modelled | IHME |
| 1.94 (1.90 - 1.98) | 1992 | Modelled | IHME |
| 1.94 (1.90 - 1.98) | 1991 | Modelled | IHME |
| 1.93 (1.89 - 1.98) | 1990 | Modelled | IHME |
| 2.09 (1.48 - 2.83) | 2015 | Modelled | WHO |
| 2.9 (2.38 - 3.51) | 2017 | Survey/reported | Kasradze et al, 2017 |
| 2.64 (2.22 - 3.14) | 2013 | Modelled | Schweitzer et al, 2015 |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.24 (0.21 - 0.28) | 2019 | Modelled | IHME |
| 0.26 (0.23 - 0.28) | 2018 | Modelled | IHME |
| 0.26 (0.23 - 0.29) | 2017 | Modelled | IHME |
| 0.26 (0.23 - 0.29) | 2016 | Modelled | IHME |
| 0.26 (0.22 - 0.30) | 2015 | Modelled | IHME |
| 0.26 (0.22 - 0.30) | 2014 | Modelled | IHME |
| 0.27 (0.23 - 0.31) | 2013 | Modelled | IHME |
| 0.28 (0.24 - 0.32) | 2012 | Modelled | IHME |
| 0.29 (0.24 - 0.33) | 2011 | Modelled | IHME |
| 0.31 (0.25 - 0.34) | 2010 | Modelled | IHME |
| 0.34 (0.29 - 0.38) | 2009 | Modelled | IHME |
| 0.41 (0.35 - 0.45) | 2008 | Modelled | IHME |
| 0.49 (0.43 - 0.54) | 2007 | Modelled | IHME |
| 0.58 (0.51 - 0.64) | 2006 | Modelled | IHME |
| 0.67 (0.58 - 0.75) | 2005 | Modelled | IHME |
| 0.76 (0.64 - 0.85) | 2004 | Modelled | IHME |
| 0.85 (0.70 - 0.98) | 2003 | Modelled | IHME |
| 0.95 (0.75 - 1.11) | 2002 | Modelled | IHME |
| 1.05 (0.80 - 1.23) | 2001 | Modelled | IHME |
| 1.13 (0.86 - 1.33) | 2000 | Modelled | IHME |
| 1.21 (0.94 - 1.41) | 1999 | Modelled | IHME |
| 1.31 (1.05 - 1.49) | 1998 | Modelled | IHME |
| 1.39 (1.16 - 1.56) | 1997 | Modelled | IHME |
| 1.45 (1.24 - 1.61) | 1996 | Modelled | IHME |
| 1.47 (1.27 - 1.64) | 1995 | Modelled | IHME |
| 1.47 (1.27 - 1.63) | 1994 | Modelled | IHME |
| 1.47 (1.26 - 1.63) | 1993 | Modelled | IHME |
| 1.46 (1.24 - 1.62) | 1992 | Modelled | IHME |
| 1.45 (1.19 - 1.62) | 1991 | Modelled | IHME |
| 1.42 (1.13 - 1.63) | 1990 | Modelled | IHME |
| 0.26 (0.16 - 0.42) | 2015 | Modelled | WHO |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 10 (7.31 - 13.50) | 2019 | Modelled | IHME |
| 9.57 (7.21 - 12.60) | 2018 | Modelled | IHME |
| 9.42 (7.11 - 12.30) | 2017 | Modelled | IHME |
| 9.7 (7.40 - 12.60) | 2016 | Modelled | IHME |
| 9.94 (7.63 - 12.80) | 2015 | Modelled | IHME |
| 10.1 (7.82 - 13.10) | 2014 | Modelled | IHME |
| 10.6 (8.06 - 13.70) | 2013 | Modelled | IHME |
| 10.9 (8.33 - 13.90) | 2012 | Modelled | IHME |
| 11.1 (8.53 - 14.10) | 2011 | Modelled | IHME |
| 11.1 (8.62 - 14.10) | 2010 | Modelled | IHME |
| 11.1 (8.69 - 14) | 2009 | Modelled | IHME |
| 11.1 (8.63 - 14) | 2008 | Modelled | IHME |
| 11 (8.55 - 13.90) | 2007 | Modelled | IHME |
| 11.2 (8.76 - 13.90) | 2006 | Modelled | IHME |
| 11.4 (8.80 - 14.10) | 2005 | Modelled | IHME |
| 11.6 (9.04 - 14.70) | 2004 | Modelled | IHME |
| 11.3 (8.69 - 14) | 2003 | Modelled | IHME |
| 11.2 (8.64 - 14) | 2002 | Modelled | IHME |
| 10.8 (8.40 - 13.70) | 2001 | Modelled | IHME |
| 10.7 (8.22 - 13.50) | 2000 | Modelled | IHME |
| 10.4 (7.99 - 13.20) | 1999 | Modelled | IHME |
| 9.76 (7.45 - 12.40) | 1998 | Modelled | IHME |
| 9.05 (6.82 - 11.50) | 1997 | Modelled | IHME |
| 8.65 (6.55 - 10.90) | 1996 | Modelled | IHME |
| 8.83 (6.72 - 11.20) | 1995 | Modelled | IHME |
| 9.25 (7.04 - 11.80) | 1994 | Modelled | IHME |
| 9.09 (6.81 - 11.60) | 1993 | Modelled | IHME |
| 9.3 (7.02 - 11.90) | 1992 | Modelled | IHME |
| 9.18 (6.85 - 11.80) | 1991 | Modelled | IHME |
| 8.97 (6.67 - 11.50) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 367 (268 - 493) | 2019 | Modelled | IHME |
| 354 (267 - 467) | 2018 | Modelled | IHME |
| 351 (265 - 459) | 2017 | Modelled | IHME |
| 365 (279 - 475) | 2016 | Modelled | IHME |
| 377 (290 - 484) | 2015 | Modelled | IHME |
| 388 (299 - 500) | 2014 | Modelled | IHME |
| 410 (311 - 531) | 2013 | Modelled | IHME |
| 424 (324 - 542) | 2012 | Modelled | IHME |
| 435 (336 - 554) | 2011 | Modelled | IHME |
| 443 (343 - 563) | 2010 | Modelled | IHME |
| 448 (351 - 566) | 2009 | Modelled | IHME |
| 455 (353 - 574) | 2008 | Modelled | IHME |
| 455 (354 - 576) | 2007 | Modelled | IHME |
| 472 (369 - 585) | 2006 | Modelled | IHME |
| 486 (377 - 604) | 2005 | Modelled | IHME |
| 508 (394 - 640) | 2004 | Modelled | IHME |
| 502 (386 - 624) | 2003 | Modelled | IHME |
| 508 (392 - 637) | 2002 | Modelled | IHME |
| 501 (389 - 634) | 2001 | Modelled | IHME |
| 507 (389 - 639) | 2000 | Modelled | IHME |
| 501 (385 - 638) | 1999 | Modelled | IHME |
| 480 (367 - 609) | 1998 | Modelled | IHME |
| 454 (342 - 575) | 1997 | Modelled | IHME |
| 441 (334 - 558) | 1996 | Modelled | IHME |
| 458 (349 - 583) | 1995 | Modelled | IHME |
| 487 (371 - 624) | 1994 | Modelled | IHME |
| 486 (364 - 623) | 1993 | Modelled | IHME |
| 504 (380 - 646) | 1992 | Modelled | IHME |
| 502 (375 - 647) | 1991 | Modelled | IHME |
| 494 (368 - 633) | 1990 | Modelled | IHME |
| 800 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 22 (16 - 30) | 2019 | Modelled | IHME |
| 22 (16 - 30) | 2018 | Modelled | IHME |
| 22 (16 - 30) | 2017 | Modelled | IHME |
| 22 (16 - 30) | 2016 | Modelled | IHME |
| 22 (16 - 30) | 2015 | Modelled | IHME |
| 23 (17 - 30) | 2014 | Modelled | IHME |
| 23 (17 - 31) | 2013 | Modelled | IHME |
| 23 (17 - 31) | 2012 | Modelled | IHME |
| 23 (17 - 31) | 2011 | Modelled | IHME |
| 23 (17 - 31) | 2010 | Modelled | IHME |
| 23 (17 - 31) | 2009 | Modelled | IHME |
| 23 (17 - 31) | 2008 | Modelled | IHME |
| 23 (17 - 31) | 2007 | Modelled | IHME |
| 23 (17 - 31) | 2006 | Modelled | IHME |
| 23 (16 - 31) | 2005 | Modelled | IHME |
| 23 (16 - 31) | 2004 | Modelled | IHME |
| 23 (17 - 32) | 2003 | Modelled | IHME |
| 24 (17 - 33) | 2002 | Modelled | IHME |
| 24 (17 - 33) | 2001 | Modelled | IHME |
| 24 (17 - 33) | 2000 | Modelled | IHME |
| 24 (17 - 33) | 1999 | Modelled | IHME |
| 24 (17 - 34) | 1998 | Modelled | IHME |
| 24 (17 - 33) | 1997 | Modelled | IHME |
| 24 (17 - 33) | 1996 | Modelled | IHME |
| 23 (17 - 32) | 1995 | Modelled | IHME |
| 23 (17 - 32) | 1994 | Modelled | IHME |
| 23 (16 - 31) | 1993 | Modelled | IHME |
| 23 (17 - 31) | 1992 | Modelled | IHME |
| 23 (16 - 31) | 1991 | Modelled | IHME |
| 23 (16 - 31) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of HepB birth dose
Newborns
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 97 | 2018 | Survey/reported | WHO/UNICEF |
| 94 | 2017 | Survey/reported | WHO/UNICEF |
| 94 | 2016 | Survey/reported | WHO/UNICEF |
| 93 | 2015 | Survey/reported | WHO/UNICEF |
| 95 | 2014 | Survey/reported | WHO/UNICEF |
| 80 | 2013 | Survey/reported | WHO/UNICEF |
| 92 | 2012 | Survey/reported | WHO/UNICEF |
| 93 | 2011 | Survey/reported | WHO/UNICEF |
| 95 | 2010 | Survey/reported | WHO/UNICEF |
| 73 | 2009 | Survey/reported | WHO/UNICEF |
| 99 | 2008 | Survey/reported | WHO/UNICEF |
| 99 | 2007 | Survey/reported | WHO/UNICEF |
| 97 | 2006 | Survey/reported | WHO/UNICEF |
| 93 | 2005 | Survey/reported | WHO/UNICEF |
| 92 | 2004 | Survey/reported | WHO/UNICEF |
| 90 | 2003 | Survey/reported | WHO/UNICEF |
| 80 | 2002 | Survey/reported | WHO/UNICEF |
| 69 | 2001 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 93 | 2018 | Survey/reported | WHO/UNICEF |
| 91 | 2017 | Survey/reported | WHO/UNICEF |
| 92 | 2016 | Survey/reported | WHO/UNICEF |
| 94 | 2015 | Survey/reported | WHO/UNICEF |
| 91 | 2014 | Survey/reported | WHO/UNICEF |
| 96 | 2013 | Survey/reported | WHO/UNICEF |
| 92 | 2012 | Survey/reported | WHO/UNICEF |
| 89 | 2011 | Survey/reported | WHO/UNICEF |
| 95 | 2010 | Survey/reported | WHO/UNICEF |
| 54 | 2009 | Survey/reported | WHO/UNICEF |
| 89 | 2008 | Survey/reported | WHO/UNICEF |
| 94 | 2007 | Survey/reported | WHO/UNICEF |
| 84 | 2006 | Survey/reported | WHO/UNICEF |
| 79 | 2005 | Survey/reported | WHO/UNICEF |
| 64 | 2004 | Survey/reported | WHO/UNICEF |
| 48 | 2003 | Survey/reported | WHO/UNICEF |
| 51 | 2002 | Survey/reported | WHO/UNICEF |
| 61 | 2001 | Survey/reported | WHO/UNICEF |
| 55 | 2000 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 31 (16 - 271) | 2015 | Survey/reported | Georgia National Centre for Disease Control and Public Health, 2015; Curatio International Foundation, 2015; Eurasia Harm Reduction Network, 2015 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.9 (3.10 - 4.80) | 2015 | Survey/reported | Curatio International Foundation, 2015 |
HBV National Action Plan
Eligible for HBV generic medicines
Year of birth dose introduction
2001
HepB birth dose policy
Yes
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based, Birth cohort
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.48 (2.81 - 4.24) | 2019 | Modelled | IHME |
| 3.5 (2.82 - 4.26) | 2018 | Modelled | IHME |
| 3.51 (2.83 - 4.27) | 2017 | Modelled | IHME |
| 3.49 (2.84 - 4.26) | 2016 | Modelled | IHME |
| 3.48 (2.85 - 4.25) | 2015 | Modelled | IHME |
| 3.54 (2.93 - 4.29) | 2014 | Modelled | IHME |
| 3.68 (3.08 - 4.40) | 2013 | Modelled | IHME |
| 3.85 (3.26 - 4.54) | 2012 | Modelled | IHME |
| 4 (3.38 - 4.67) | 2011 | Modelled | IHME |
| 4.06 (3.44 - 4.75) | 2010 | Modelled | IHME |
| 4.06 (3.44 - 4.75) | 2009 | Modelled | IHME |
| 4.06 (3.44 - 4.75) | 2008 | Modelled | IHME |
| 4.06 (3.44 - 4.74) | 2007 | Modelled | IHME |
| 4.06 (3.43 - 4.75) | 2006 | Modelled | IHME |
| 4.06 (3.41 - 4.75) | 2005 | Modelled | IHME |
| 4.08 (3.43 - 4.76) | 2004 | Modelled | IHME |
| 4.11 (3.46 - 4.80) | 2003 | Modelled | IHME |
| 4.14 (3.48 - 4.86) | 2002 | Modelled | IHME |
| 4.17 (3.49 - 4.91) | 2001 | Modelled | IHME |
| 4.18 (3.50 - 4.93) | 2000 | Modelled | IHME |
| 4.14 (3.46 - 4.85) | 1999 | Modelled | IHME |
| 4.03 (3.36 - 4.76) | 1998 | Modelled | IHME |
| 3.9 (3.21 - 4.63) | 1997 | Modelled | IHME |
| 3.77 (3.08 - 4.53) | 1996 | Modelled | IHME |
| 3.67 (2.96 - 4.47) | 1995 | Modelled | IHME |
| 3.61 (2.92 - 4.41) | 1994 | Modelled | IHME |
| 3.55 (2.88 - 4.35) | 1993 | Modelled | IHME |
| 3.5 (2.82 - 4.29) | 1992 | Modelled | IHME |
| 3.46 (2.77 - 4.25) | 1991 | Modelled | IHME |
| 3.43 (2.76 - 4.25) | 1990 | Modelled | IHME |
| 5.4 (4.60 - 6.40) | 2015 | Survey/reported | Hagan et al, 2015 |
| 4.2 (3 - 4.20) | 2015 | Modelled | Blach et al, 2017 |
Showing out of
Show more
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 8.9 | 2018 | Survey/reported | Averhoff A et al, 2020 |
| 6.7 (5.60 - 7.30) | 2014 | Modelled | Gower et al, 2014 |
| 7.7 (6.70 - 8.90) | 2015 | Survey/reported | Hagan et al, 2015 |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 69.1 (58 - 80.20) | 2015 | Modelled | Degenhardt L et al, 2017 |
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 10 (7.47 - 13.40) | 2019 | Modelled | IHME |
| 10.2 (7.72 - 13.50) | 2018 | Modelled | IHME |
| 10.2 (7.79 - 13.50) | 2017 | Modelled | IHME |
| 10.1 (7.84 - 13.10) | 2016 | Modelled | IHME |
| 9.71 (7.58 - 12.70) | 2015 | Modelled | IHME |
| 9.47 (7.33 - 12.30) | 2014 | Modelled | IHME |
| 9.52 (7.32 - 12.30) | 2013 | Modelled | IHME |
| 9.27 (7.09 - 12) | 2012 | Modelled | IHME |
| 9.11 (6.97 - 11.80) | 2011 | Modelled | IHME |
| 8.86 (6.78 - 11.50) | 2010 | Modelled | IHME |
| 8.5 (6.49 - 11) | 2009 | Modelled | IHME |
| 8.2 (6.25 - 10.50) | 2008 | Modelled | IHME |
| 7.82 (5.97 - 10.10) | 2007 | Modelled | IHME |
| 7.84 (6.06 - 10.10) | 2006 | Modelled | IHME |
| 7.89 (6.11 - 10) | 2005 | Modelled | IHME |
| 8.12 (6.32 - 10.30) | 2004 | Modelled | IHME |
| 8.01 (6.23 - 10.20) | 2003 | Modelled | IHME |
| 8.07 (6.32 - 10.20) | 2002 | Modelled | IHME |
| 8.06 (6.37 - 10.20) | 2001 | Modelled | IHME |
| 8.04 (6.36 - 10.20) | 2000 | Modelled | IHME |
| 7.73 (6 - 9.94) | 1999 | Modelled | IHME |
| 7.12 (5.46 - 9.19) | 1998 | Modelled | IHME |
| 6.36 (4.84 - 8.41) | 1997 | Modelled | IHME |
| 5.99 (4.46 - 7.94) | 1996 | Modelled | IHME |
| 6.01 (4.48 - 7.91) | 1995 | Modelled | IHME |
| 6.23 (4.62 - 8.29) | 1994 | Modelled | IHME |
| 6.09 (4.53 - 8.07) | 1993 | Modelled | IHME |
| 6.19 (4.65 - 8.42) | 1992 | Modelled | IHME |
| 6.07 (4.50 - 8.24) | 1991 | Modelled | IHME |
| 5.91 (4.30 - 8.07) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 367 (274 - 490) | 2019 | Modelled | IHME |
| 376 (286 - 501) | 2018 | Modelled | IHME |
| 381 (291 - 504) | 2017 | Modelled | IHME |
| 379 (295 - 494) | 2016 | Modelled | IHME |
| 368 (288 - 483) | 2015 | Modelled | IHME |
| 362 (281 - 471) | 2014 | Modelled | IHME |
| 367 (282 - 474) | 2013 | Modelled | IHME |
| 361 (276 - 467) | 2012 | Modelled | IHME |
| 359 (274 - 465) | 2011 | Modelled | IHME |
| 353 (270 - 457) | 2010 | Modelled | IHME |
| 343 (262 - 442) | 2009 | Modelled | IHME |
| 335 (256 - 430) | 2008 | Modelled | IHME |
| 324 (248 - 417) | 2007 | Modelled | IHME |
| 330 (255 - 424) | 2006 | Modelled | IHME |
| 338 (261 - 429) | 2005 | Modelled | IHME |
| 354 (276 - 450) | 2004 | Modelled | IHME |
| 356 (277 - 452) | 2003 | Modelled | IHME |
| 366 (287 - 463) | 2002 | Modelled | IHME |
| 374 (295 - 473) | 2001 | Modelled | IHME |
| 380 (301 - 482) | 2000 | Modelled | IHME |
| 373 (290 - 479) | 1999 | Modelled | IHME |
| 351 (269 - 452) | 1998 | Modelled | IHME |
| 319 (243 - 422) | 1997 | Modelled | IHME |
| 306 (227 - 405) | 1996 | Modelled | IHME |
| 312 (232 - 410) | 1995 | Modelled | IHME |
| 329 (243 - 437) | 1994 | Modelled | IHME |
| 326 (243 - 431) | 1993 | Modelled | IHME |
| 335 (252 - 456) | 1992 | Modelled | IHME |
| 332 (246 - 451) | 1991 | Modelled | IHME |
| 325 (237 - 445) | 1990 | Modelled | IHME |
| 425 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 34 (25 - 43) | 2019 | Modelled | IHME |
| 34 (26 - 43) | 2018 | Modelled | IHME |
| 34 (26 - 43) | 2017 | Modelled | IHME |
| 35 (26 - 44) | 2016 | Modelled | IHME |
| 35 (26 - 44) | 2015 | Modelled | IHME |
| 35 (26 - 44) | 2014 | Modelled | IHME |
| 35 (26 - 44) | 2013 | Modelled | IHME |
| 35 (27 - 44) | 2012 | Modelled | IHME |
| 36 (27 - 44) | 2011 | Modelled | IHME |
| 36 (27 - 45) | 2010 | Modelled | IHME |
| 36 (27 - 45) | 2009 | Modelled | IHME |
| 36 (27 - 45) | 2008 | Modelled | IHME |
| 36 (27 - 46) | 2007 | Modelled | IHME |
| 37 (28 - 46) | 2006 | Modelled | IHME |
| 38 (28 - 46) | 2005 | Modelled | IHME |
| 38 (28 - 47) | 2004 | Modelled | IHME |
| 37 (28 - 47) | 2003 | Modelled | IHME |
| 37 (27 - 47) | 2002 | Modelled | IHME |
| 37 (28 - 47) | 2001 | Modelled | IHME |
| 37 (27 - 47) | 2000 | Modelled | IHME |
| 37 (28 - 47) | 1999 | Modelled | IHME |
| 37 (27 - 47) | 1998 | Modelled | IHME |
| 37 (28 - 47) | 1997 | Modelled | IHME |
| 37 (28 - 47) | 1996 | Modelled | IHME |
| 37 (28 - 47) | 1995 | Modelled | IHME |
| 37 (28 - 47) | 1994 | Modelled | IHME |
| 37 (28 - 47) | 1993 | Modelled | IHME |
| 37 (28 - 46) | 1992 | Modelled | IHME |
| 37 (28 - 46) | 1991 | Modelled | IHME |
| 37 (28 - 46) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 300 (16 - 271) | 2015 | Survey/reported | Georgia National Centre for Disease Control and Public Health, 2015; Curatio International Foundation, 2015; Eurasia Harm Reduction Network, 2015 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.9 (3.10 - 4.80) | 2015 | Survey/reported | Curatio International Foundation, 2015 |
HBV National Action Plan
Eligible for HBV generic medicines
Year of birth dose introduction
2001
HepB birth dose policy
Yes
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based, Birth cohort
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None
Overview
HCV elimination goal
Year of goal
2030
Prevalence (national)
Modelled
HBV (HBsAg+)
1.48
(%)
2019
(1.46 - 1.5(%))
IHME
HCV (RNA/cAg+)
3.48
(%)
2019
(2.81 - 4.24(%))
IHME
Survey/surveillance
HBV (HBsAg+)
2.9
(%)
2017
(2.38 - 3.51(%))
Kasradze et al, 2017
HCV (anti-HCV)
8.9
(%)
2018
Averhoff A et al, 2020
Hepatitis related deaths (national)
Modelled
HBV
367
2019
(268 - 493)
IHME
Survey/surveillance
No data available
HBV chart
Modelled
HCV
367
2019
(274 - 490)
IHME
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.24
(%)
2019, latest modelled
(0.21 - 0.28(%))
IHME
Prevalence PWID
HCV
69.10
(%)
2015, latest modelled
(58 - 80.20(%))
Degenhardt L et al, 2017
Birth dose vaccination coverage (national)
Survey/surveillance
HBV
97
(%)
2018
WHO/UNICEF
No. of syringes/PWID/year
Survey/surveillance
HCV
31
2015
(16 - 271)
Georgia National Centre for Disease Control and Public Health, 2015; Curatio International Foundation, 2015; Eurasia Harm Reduction Network, 2015
Eligible for HBV generic medicines
Eligible for HCV generic medicines
